财务数据关键指标变化：收入 - 2025年第四季度收入为380万美元，同比增长180万美元或94.9%[5] - 2025年全年收入为1130万美元，同比增长260万美元或30.0%[9] - 第四季度营收为384.76万美元，同比增长95%[29] - 全年营收为1129.79万美元，同比增长30%[29] 财务数据关键指标变化：毛利润与毛利率 - 2025年第四季度毛利润为330万美元，毛利率从去年同期的45.8%提升至85.0%[5] - 第四季度毛利润为327.24万美元，毛利率为85%[29] - 全年毛利润为920.46万美元，毛利率为81%[29] 财务数据关键指标变化：净利润与每股收益 - 2025年第四季度净利润为80万美元，去年同期为净亏损290万美元[6] - 2025年全年净利润为680万美元，合每股1.43美元，去年同期为净亏损300万美元，合每股亏损0.94美元[10] - 第四季度归属于公司的净收入为83.93万美元，去年同期净亏损为286.07万美元[29] - 全年归属于公司的净收入为692.81万美元，去年同期净亏损为275.3万美元[29] - 第四季度基本和稀释后每股收益为0.15美元，去年同期为每股亏损0.89美元[29] - 全年基本和稀释后每股收益为1.43美元，去年同期为每股亏损0.94美元[29] 财务数据关键指标变化：运营利润 - 第四季度运营收入为57.5万美元，去年同期运营亏损为66.14万美元[29] - 全年运营收入为324.88万美元，去年同期运营亏损为174.99万美元[29] 财务数据关键指标变化：调整后息税折旧摊销前利润 - 2025年全年调整后息税折旧摊销前利润为730万美元，去年同期为亏损390万美元[11] 财务数据关键指标变化：现金流与现金状况 - 截至2025年12月31日，公司现金及现金等价物约为500万美元，到2026年2月28日增至600万美元[14] - 2025年全年经营活动产生现金410万美元[7] 业务线表现：玩家增长 - 2025年Steam平台平均同时在线玩家增长超五倍，并于2026年1月达到8,740人的历史峰值[3] 其他重要内容：融资与信贷 - 公司从花旗银行获得了300万美元的循环信贷额度[7]

Exhibit 99.1 For Immediate Release Contact 1.650.607.0349 1.212.508.7935 Ken Bond Deborah Hellinger Oracle Investor Relations Oracle Corporate Communications ken.bond@oracle.com deborah.hellinger@oracle.com Oracle Announces Fiscal Year 2026 Third Quarter Financial Results AUSTIN, Texas, March 10, 2026 -- Oracle Corporation (NYSE: ORCL) today announced that Q3 fiscal 2026 was an exceptional quarter with financial results that exceeded expectations. This Q3 was the first quarter in over 15 years where organic ...

Exhibit 99.1 Westrock Coffee Company Reports Fourth Quarter and Full Year 2025 Results and Updates 2026 Outlook Little Rock, Ark., March 10, 2026 (GLOBE NEWSWIRE) – Westrock Coffee Company (Nasdaq: WEST) ("Westrock Coffee" or the "Company") today reported financial results for the fourth quarter and full year ended December 31, 2025 and updates its outlook for 2026. Full Year 2025 Highlights 1 3 Segment Adjusted EBITDA is a segment performance measure, which is required by U.S. GAAP to be disclosed in accor ...

Exhibit 99.1 TransAct Technologies Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results Welcomed New Chief Marketing Officer, Dana Loof, in the Fourth Quarter Full Year 2025 Net Sales up 19% and Recurring FST Revenue up 14% Year-over-Year Guides to 2026 Revenue of $55-$57 Million, Driven by Anticipated High Margin Software Sales Hamden, CT –March 10, 2026 – TransAct Technologies Incorporated (Nasdaq: TACT) ("TransAct" or the "Company"), a global leader in software-driven technology and pr ...

财务数据关键指标变化：收入 - 第四季度总收入为5550万美元，同比下降35.7%[5] - 2025财年总收入为2.517亿美元，同比下降39.9%[5] - 2025年总营收为2.517亿美元，较2024年的4.188亿美元下降39.9%[22] 财务数据关键指标变化：利润与亏损 - 第四季度净利润为520万美元，去年同期净亏损3460万美元[5] - 2025财年净亏损290万美元，较上年净亏损7160万美元收窄95.9%[8][9] - 2025年净亏损为286万美元，较2024年净亏损7164万美元大幅收窄96.0%[22] - 2025年第四季度实现净利润521.9万美元，而2024年同期净亏损3455.8万美元[22] - 2025年第四季度净收入为521.9万美元，2024年同期净亏损为3455.8万美元；2025全年净亏损为286.0万美元，2024全年净亏损为7164.2万美元[28][37] - 2025年第四季度调整后净收入为721.1万美元，2024年同期调整后净亏损为471.3万美元；2025全年调整后净收入为346.3万美元，2024全年调整后净亏损为3121.9万美元[37] 财务数据关键指标变化：调整后EBITDA - 第四季度调整后EBITDA为1290万美元，同比增长48.0%[9] - 2025财年调整后EBITDA为3080万美元，同比增长8.8%[8][9] - 2025年第四季度调整后EBITDA为1287.8万美元，2024年同期为869.9万美元；2025全年调整后EBITDA为3076.7万美元，2024全年为2831.7万美元[28] 财务数据关键指标变化：现金流 - 2025财年实现正自由现金流1740万美元，上年为负200万美元[8] - 2025年经营活动产生的现金流量净额为2175万美元，较2024年的256.2万美元大幅增长749.1%[24] - 2025年自由现金流为1735.1万美元，而2024年为负198.0万美元[45] 财务数据关键指标变化：成本与费用 - 2025年总运营费用为1.783亿美元，较2024年的3.536亿美元下降49.6%[22] 各条业务线表现 - 2025年数字业务营收为1.533亿美元，营养及其他业务营收为9757.1万美元，分别同比下降31.7%和48.1%[22] 管理层讨论和指引 - 2026年第一季度收入指引为4900万至5400万美元[10] - 2026年第一季度调整后EBITDA指引为400万至700万美元[10] 其他重要内容：现金与债务状况 - 公司现金状况强劲，资产负债表上现金超过3900万美元[2] - 2025年现金及现金等价物为3901.7万美元，较上年末的2018.7万美元增长93.3%[20][24] - 2025年5月公司偿还了1730万美元债务，导致全年确认了216.6万美元债务清偿损失[28][37] - 2024年公司进行了多笔部分债务提前偿还（总计100万、550万、400万和320万美元），导致全年确认了237.9万美元债务清偿损失[28][37] - 截至2025年12月31日，公司净现金头寸为1539.1万美元，较2024年同期的101.9万美元大幅改善[43] 其他重要内容：重组计划影响 - 2024年第四季度因“Pivot”重组计划确认了930.5万美元成本，2024全年确认了1846.4万美元成本，包括818.9万美元（季度）和1112.5万美元（全年）的加速折旧[37][48] - 2024年第四季度“Pivot”重组计划导致约170名员工被裁减，占当时员工总数的33%[46] - 2024年因“Pivot”重组，对账面净值约1280万美元的长期资产进行了加速折旧，其平均剩余使用寿命从25个月缩短至3个月[48] 其他重要内容：其他财务数据 - 2025年末总资产为1.470亿美元，总负债为1.157亿美元，股东权益为3132万美元[20] - 2025年递延收入为5686.6万美元，较2024年末的7727.3万美元下降26.4%[20] - 2025年存货为941万美元，较2024年末的1630.3万美元下降42.3%[20]

Net Income Reported for Second Consecutive Quarter Net Income and Adjusted EBITDA Better Than Guidance Revenues Above Mid-Point of Guidance Ninth Consecutive Quarter of Positive Adjusted EBITDA Full Year Operating Income Reported for First Time Since Going Public in 2021 Positive Free Cash Flow For the Full Year El Segundo, Calif. (March 10, 2026) – The Beachbody Company, Inc. (NASDAQ: BODi) ("BODi" or the "Company"), a leading fitness and nutrition company, today announced financial results for its fourth ...

Exhibit 99.1 Evolv Technology Reports Fourth Quarter Financial Results — Company Raises Outlook for 2026 — Waltham, Massachusetts – March 10, 2026 – Evolv Technologies Holdings, Inc (NASDAQ: EVLV), a leading security technology company pioneering AI-based solutions designed to help create safer experiences, today announced financial results for the year ended December 31, 2025. "We are pleased to be reporting solid fourth quarter results, which capped a year of significant improvement across the Company," s ...

Exhibit 99.1 Results for the Fourth Quarter of 2025 Total revenue for the fourth quarter of 2025 was $38.5 million, an increase of 32% compared to $29.1 million for the fourth quarter of 2024. Revenue for the fourth quarter of 2025 was primarily driven by strong new customer additions and continued expansion of deployments across the existing customer base. Annual Recurring Revenue ("ARR") was $120.5 million at the end of fourth quarter of 2025, an increase of 21% compared to $99.4 million at the end of the ...

Exhibit 99.1 Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal trial design for AlloNK expected in first half of 2026 Strengthened board and executive leadership with deep immunology, commercial and financial expertise About Artiva Biotherapeutics Artiva is a clinical-sta ...

Fourth quarter 2025 highlights: loanDepot announces year-end and fourth quarter 2025 financial results Delivered highest quarterly loan origination volume since 2022. Grew market share 19% while investing in digital infrastructure to scale for growth. Full-year 2025 highlights: IRVINE, Calif., March 10, 2026 - loanDepot, Inc. (NYSE: LDI), (together with its subsidiaries, "loanDepot" or the "Company"), today announced results for the year-end and fourth quarter ended December 31, 2025. "In the fourth quarter ...